Syndrome Scale (PANSS) total score <75; and (ii) a score <3 for all PANSS parameters, namely, conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content. Informed consent was obtained and the patients' anonymity has been preserved.
The two outpatients were a 24-year-old woman with paranoid schizophrenia (duration of illness, 6 years) who experienced bradykinesia, dystonia, and dyskinesia under paliperidone palmitate LAI treatment (50 mg); and a 58-yearold man with disorganized schizophrenia (duration of illness, 27 years) who experienced bradykinesia, akathisia, and dyskinesia under aripiprazole once-monthly treatment (400 mg). Six months after the LAI dosing intervals were extended from 4 weeks to 6 weeks, the following characteristics improved: PANSS negative score (female patient: 19 to 13; male patient: 26 to 24), Drug-Induced Extrapyramidal Symptoms Scale (female patient: 6 to 3; male patient: 7 to 4), Abnormal Involuntary Movement Scale (female patient: 8 to 4; male patient: 6 to 3), and Barnes Akathisia Scale (female patient: 0 to 0; male patient: 3 to 0). The PANSS Positive score remained unchanged (11 in both). The patients were taking no other drugs.
In this study, the LAI dosing intervals were extended from 4 weeks to 6 weeks in order to improve EPS and negative symptoms to some extent during maintenance therapy. The psychiatric symptoms were stable during therapy, leading to improved quality of life and living skills. In clinical practice, the dosing interval is generally prescribed on the basis of serum half-life, although its validity has not been investigated thoroughly. Consistent with previous studies, 1 it is suggested that extended dosing intervals of LAI in stabilized schizophrenic patients improve the negative symptoms, bradykinesia, akathisia, dystonia, and dyskinesia, without increasing the risk of a relapse. Consistent with this case report, earlier studies have suggested new treatment possibilities as a result of extending the traditionally prescribed dosing interval of oral antipsychotic drugs.
2 Therefore, the results indicate the possibility of lessened adverse effects as a result of extending the dosing interval of LAI in the maintenance phase.
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